Brad Spellberg, MD (Chair) Print E-mail
Assistant Professor of Medicine,
David Geffen School of Medicine at UCLA,
Division of Infectious Diseases,
Department of Medicine,
Harbor-UCLA Medical Center,
Torrance, California, USA

Brad Spellberg is an Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, and is based in the Division of Infectious Diseases at Harbor-UCLA Medical Center.  He received his BA in Molecular Cell Biology-Immunology in 1994 from UC Berkeley.  He then attended medical school at the Geffen School of Medicine at UCLA, where he received numerous academic honors, including serving as the UCLA AOA Chapter Co-President, and winning the prestigious Stafford Warren award for the topic academic performance in his graduating class.  Dr. Spellberg completed his Residency in Internal Medicine and subspecialty fellowship in Infectious Diseases at Harbor-UCLA Medical Center, where he received the Department of Medicine Subspecialty Fellow of the Year award.

Dr. Spellberg's research focuses on using the immune system to prevent and/or treat infections.  For the last several years he has worked to develop a vaccine that targets the bacterium Staphylococcus aureus and the fungus Candida, which are the second and third most common causes of bloodstream infections.  He co-founded NovaDigm Therapeutics, Inc., a biotechnology company, to translate the vaccine from the bench to the bedside.  Dr. Spellberg is also developing genetically engineered white blood cells that recapitulate neutrophil functions and can be used to overcome the technical barriers to neutrophil transfusion therapy for neutropenic infections.  He has also worked in close collaboration with Dr. Ashraf Ibrahim to study the use of iron chelation therapy for the lethal infection, mucormycosis.  He is currently the Principle Investigator of a multi-centered, randomized clinical trial to study this novel treatment.

Finally, Dr. Spellberg established the first auditable, peer-reviewed dataset that confirms the decline in new antibiotic development over the last two decades, underscoring the need for development of new immune-based therapies for infections.  He has worked with staff members at the Infectious Diseases Society of America (IDSA) to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics.  His dataset regarding new drug development has been a cornerstone of the IDSA's white paper, Bad Bugs, No Drugs, and has been cited extensively in medical literature and on capital hill.  He has recently been named a Fellow in the IDSA and joined the IDSA's Antimicrobial Availability Task Force to continue working on this critical problem.

Next >

Organized by:
ASM wishes to recognize Astellas Pharma, US, Inc., for providing an educational grant to support MRSA-I